A multicenter, open-label phase IV study to evaluate overall health, physical activity, and joint outcomes, in participants aged = 13 and < 70 years with severe or moderate hemophilia A without FVIII inhibitors on emicizumab prophylaxis

F. Hoffmann-La Roche Ltd (Switzerland)0 sites14 target enrollmentMay 13, 2022

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Not specified
Sponsor: F. Hoffmann-La Roche Ltd (Switzerland)
Enrollment: 14
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

May 13, 2022

End Date

April 20, 2027

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

F. Hoffmann-La Roche Ltd (Switzerland)

Eligibility Criteria

Inclusion Criteria

•1\. Age \>\=13 and \<70 years at time of signing Informed Consent Form
•2\. Diagnosis of severe congenital hemophilia A (intrinsic FVIII level \<1%) or moderate congenital hemophilia A (intrinsic FVIII level \<\=5%) if previously prescribed prophylaxis
•3\. A negative test for FVIII inhibitor (i.e., \<0\.6 BU) within 8 weeks of enrollment
•4\. Participants who completed successful immune tolerance induction (ITI) at least 5 years before screening are eligible, provided they have had no evidence of inhibitor recurrence (permanent or temporary) as may be indicated by detection of an inhibitor, FVIII half\-life \< 6 hours, or FVIII recovery \< 66% since completing ITI
•5\. Participants who were on standard FVIII prophylaxis, defined as the regular administration of FVIII to prevent bleeding, for at least the last 24 weeks, can be enrolled regardless of the number of bleeds during this period
•6\. Adequate hematologic, hepatic and renal function
•7\. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for at least 24 weeks after the final dose of emicizumab

Exclusion Criteria

•1\. Inherited or acquired bleeding disorder other than severe congenital hemophilia A (intrinsic FVIII level \<1%) or moderate congenital hemophilia A (intrinsic FVIII level \<\=5%) without FVIII inhibitors who were previously prescribed prophylaxis for at least 24 weeks
•2\. Participants who have previously received emicizumab prophylaxis
•3\. Participants who had joint replacement, joint procedure, synovectomy or synoviorthesis less than 5 years ago, or participants who had joint replacement, joint procedure, synovectomy or synoviorthesis more than 5 years ago but are still experiencing pain in the joint (only the specific joint will be excluded from the study), or participants that plan to have joint replacement, joint procedure, synovectomy or synoviorthesis, or participants that are deemed suitable candidates for joint replacement, joint procedure, synovectomy or synoviorthesis at screening
•4\. Participants who have conditions other than hemophilia A that can affect joint health and structure (e.g., osteoarthritis) or with severely impaired mobility due to conditions other than hemophilia A
•5\. Participants with reduced bone mineral density defined as clinically relevant vitamin D deficiency
•6\. Participants with pre\-existing cardiovascular disease not receiving controlled and targeted medication or in a stable condition
•7\. Participants not eligible for MRI
•8\. History of illicit drug or alcohol abuse within 48 weeks prior to screening
•9\. Participants who are at high risk for thrombotic microangiopathy (TMA)
•10\. Previous (within the last 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter\-associated thrombosis for which anti\-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease